Authors and Editorial Advisors
For over 30 years, MedWorks Media has collaborated with the world’s most respected psychiatrists, psychopharmacologists, and neuroscientists. Our editorial board and contributing authors represent department chairs from premier medical institutions, pioneering researchers, and emerging thought leaders who are shaping the future of psychiatric medicine.
From Harvard and Stanford to Columbia and Emory, our network includes former presidents of major psychiatric organizations, NIH-funded investigators, and clinicians who have authored thousands of peer-reviewed publications. Their expertise spans the full spectrum of psychiatric medicine—from mood and anxiety disorders to addiction psychiatry and pharmacogenetics.
This distinguished network ensures that Psychopharmacology Bulletin and our educational resources maintain the highest standards of scientific rigor while bridging cutting-edge research with clinical practice.
Editorial Leadership
Michael E. Thase, MD
Editor-in-Chief, Psychopharmacology Bulletin
Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania
Dr. Thase directs the Depression Treatment and Research Program and has authored over 340 scientific articles focusing on mood disorders and bipolar affective disorder.
Charles B. Nemeroff, MD, PhD
Editor Emeritus, Psychopharmacology Bulletin
Leonard M. Miller Professor, University of Miami Miller School of Medicine
As founding Editor-in-Chief, Dr. Nemeroff established the journal’s reputation for excellence. He is a member of the Institute of Medicine and past President of the American College of Neuropsychopharmacology.
James M. La Rossa Jr.
Publisher & Editorial Director
Founder, MedWorks Media Inc.
Since founding MedWorks Media in 1994, Mr. La Rossa has built the premier publishing platform for psychiatric medicine, previously founding Primary Psychiatry and CNS Spectrums.
Editorial Advisory Board & Contributing Authors
Jack M. Gorman, MD
CEO and Chief Scientific Officer, Franklin Behavioral Healthcare
Dr. Gorman serves as CEO of Franklin Behavioral Healthcare and is a fellow of the American College of Neuropsychopharmacology with over 400 published scientific articles.
Alan F. Schatzberg, MD
Kenneth T. Norris Jr. Professor of Psychiatry, Stanford University School of Medicine
Dr. Schatzberg is a leading investigator in depression psychopharmacology with over 700 publications and past President of the American Psychiatric Association.
Steven E. Hyman, MD
Director, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard
Dr. Hyman leads research in psychiatric genetics, neurobiology, and drug development focused on understanding biological mechanisms underlying psychiatric disorders.
K. Ranga Rama Krishnan, MB, ChB
Professor of Psychiatry, Rush University Medical Center
Dr. Krishnan specializes in geriatric psychiatry, neuroimaging applications in psychiatric disorders, and mood disorders research.
Jeffrey A. Lieberman, MD
Professor of Psychiatry, Columbia University Irving Medical Center
Dr. Lieberman is a leading authority on schizophrenia research, psychopharmacology, and clinical psychiatry with extensive academic and clinical experience.
Philip T. Ninan, MD
Former Chief Medical Officer, Forest Research Institute
Dr. Ninan brings pharmaceutical industry experience in clinical development with expertise in anxiety disorders and mood disorders.
Myrna M. Weissman, PhD
Professor of Epidemiology in Psychiatry, Columbia University Medical Center
Dr. Weissman is a distinguished researcher in psychiatric epidemiology, depression research, and psychotherapy research.
